ArticleBMC cancer2026

SOT102, a novel CLDN18.2-targeting antibody-drug conjugate, exhibits strong therapeutic potential in solid tumors.

Iva Valentová et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.